Abstract
This report analyzes the US market for Multiple Myeloma Therapeutics in
Millions of US$. TThe market for multiple myeloma therapeutics is analyzed by
the following Drugs: Thalomid, Revlimid, Velcade, and Others. The market for
multiple myeloma therapeutics is also analyzed by the Lines of Treatment -
Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT
Candidates, and Therapy for Relapsed or Refractory Myeloma. Annual forecasts
are provided for the period of 2006 through 2015. The report profiles 98
companies including many key and niche players such as Amgen Inc., Avalon
Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Kosan Biosciences, Inc.,
Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc., Genta
Incorporated, Millennium Pharmaceuticals, Ortho Biotech Products, LP, Seattle
Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived
from primary and secondary research. Company profiles are mostly extracted
from URL research and reported select online sources.
| 
View Cart
